188 related articles for article (PubMed ID: 28065793)
1. Polyglutamine expansion of ataxin-3 alters its degree of ubiquitination and phosphorylation at specific sites.
Kristensen LV; Oppermann FS; Rauen MJ; Hartmann-Petersen R; Thirstrup K
Neurochem Int; 2017 May; 105():42-50. PubMed ID: 28065793
[TBL] [Abstract][Full Text] [Related]
2. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry analyses of normal and polyglutamine expanded ataxin-3 reveal novel interaction partners involved in mitochondrial function.
Kristensen LV; Oppermann FS; Rauen MJ; Fog K; Schmidt T; Schmidt J; Harmuth T; Hartmann-Petersen R; Thirstrup K
Neurochem Int; 2018 Jan; 112():5-17. PubMed ID: 29111377
[TBL] [Abstract][Full Text] [Related]
4. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
5. Degron capability of the hydrophobic C-terminus of the polyglutamine disease protein, ataxin-3.
Blount JR; Johnson SL; Libohova K; Todi SV; Tsou WL
J Neurosci Res; 2020 Oct; 98(10):2096-2108. PubMed ID: 32643791
[TBL] [Abstract][Full Text] [Related]
6. FipoQ/FBXO33, a Cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein.
Chen ZS; Wong AKY; Cheng TC; Koon AC; Chan HYE
J Neurochem; 2019 Jun; 149(6):781-798. PubMed ID: 30685895
[TBL] [Abstract][Full Text] [Related]
7. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV
Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474
[TBL] [Abstract][Full Text] [Related]
8. The BAG2 and BAG5 proteins inhibit the ubiquitination of pathogenic ataxin3-80Q.
Che XQ; Tang BS; Wang HF; Yan XX; Jiang H; Shen L; Xu Q; Wang GH; Zhang HN; Wang CY; Guo JF
Int J Neurosci; 2015 May; 125(5):390-4. PubMed ID: 25006867
[TBL] [Abstract][Full Text] [Related]
9. PolyQ-expanded huntingtin and ataxin-3 sequester ubiquitin adaptors hHR23B and UBQLN2 into aggregates via conjugated ubiquitin.
Yang H; Yue HW; He WT; Hong JY; Jiang LL; Hu HY
FASEB J; 2018 Jun; 32(6):2923-2933. PubMed ID: 29401586
[TBL] [Abstract][Full Text] [Related]
10. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.
Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L
PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880
[TBL] [Abstract][Full Text] [Related]
11. Polyglutamine tracts regulate beclin 1-dependent autophagy.
Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
[TBL] [Abstract][Full Text] [Related]
12. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila melanogaster.
Ristic G; Sutton JR; Libohova K; Todi SV
Neurobiol Dis; 2018 Aug; 116():78-92. PubMed ID: 29704548
[TBL] [Abstract][Full Text] [Related]
14. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23.
Blount JR; Tsou WL; Ristic G; Burr AA; Ouyang M; Galante H; Scaglione KM; Todi SV
Nat Commun; 2014 Aug; 5():4638. PubMed ID: 25144244
[TBL] [Abstract][Full Text] [Related]
16. Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models.
Matos CA; Nóbrega C; Louros SR; Almeida B; Ferreiro E; Valero J; Pereira de Almeida L; Macedo-Ribeiro S; Carvalho AL
J Cell Biol; 2016 Feb; 212(4):465-80. PubMed ID: 26880203
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
18. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3.
Toonen LJ; Schmidt I; Luijsterburg MS; van Attikum H; van Roon-Mom WM
Sci Rep; 2016 Oct; 6():35200. PubMed ID: 27731380
[TBL] [Abstract][Full Text] [Related]
20. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
